Anna Barańczyk-Kuźma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Barańczyk-Kuźma has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Alicja Chrzanowska
Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland
6 shared publications - Magdalena Mielczarek-Puta
Chair and Department of Biochemistry, Faculty of Medicine, Medical University of Warsaw
5 shared publications Wojciech Graboń
Chair and Department of Biochemistry, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
3 shared publicationsAnna Skwarek
2 shared publications- Beata Gajewska
Department of Biochemistry, Medical University of Warsaw, Warsaw, Poland
2 shared publications - Beata Kaźmierczak
Department of Biochemistry, Medical University of Warsaw, Warsaw, Poland
2 shared publications
Latest Publications
- 1 August 2018
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 124, 79-96
ERCC1-deficient cells and mice are hypersensitive to lipid peroxidation
- 1 August 2018
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 124, 79-96
ERCC1-deficient cells and mice are hypersensitive to lipid peroxidation
- 16 August 2016
- Published by Wiley in Cell Biochemistry and Function
- Vol. 34 (7) , 483-490
Lactate Formation in Primary and Metastatic Colon Cancer Cells at Hypoxia and Normoxia
High glucose consumption and lactate synthesis in aerobic glycolysis are a hallmark of cancer cells. They can form lactate also in glutaminolysis, but it is not clear how oxygen availability affects this process. We studied lactate synthesis at various oxygen levels in human primary (SW480) and metastatic (SW620) colon cancer cells cultured with L‐Ser and/or L‐Asp. Glucose and lactate levels were determined colorimetrically, amino acids by HPLC, expression of AST1‐mRNA and AST2‐mRNA by RT‐PCR.In both lines glucose consumption and lactate synthesis were higher at 10% than at 1% oxygen, and lactate/glucose ratio was increased above 2.0 by L‐Asp.AST1‐mRNA expression was independent on oxygen and cell line, but AST2‐mRNA was lower at hypoxia in SW480.We conclude that, in both cell lines at 1% hypoxia, lactate is formed mainly from glucose but at 10% normoxia also from L‐Asp. At 10% normoxia, lactate synthesis is more pronounced in primary than metastatic colon cancer cells.
- 16 August 2016
- Published by Wiley in Cell Biochemistry and Function
- Vol. 34 (7) , 483-490
Lactate Formation in Primary and Metastatic Colon Cancer Cells at Hypoxia and Normoxia
High glucose consumption and lactate synthesis in aerobic glycolysis are a hallmark of cancer cells. They can form lactate also in glutaminolysis, but it is not clear how oxygen availability affects this process. We studied lactate synthesis at various oxygen levels in human primary (SW480) and metastatic (SW620) colon cancer cells cultured with L‐Ser and/or L‐Asp. Glucose and lactate levels were determined colorimetrically, amino acids by HPLC, expression of AST1‐mRNA and AST2‐mRNA by RT‐PCR.In both lines glucose consumption and lactate synthesis were higher at 10% than at 1% oxygen, and lactate/glucose ratio was increased above 2.0 by L‐Asp.AST1‐mRNA expression was independent on oxygen and cell line, but AST2‐mRNA was lower at hypoxia in SW480.We conclude that, in both cell lines at 1% hypoxia, lactate is formed mainly from glucose but at 10% normoxia also from L‐Asp. At 10% normoxia, lactate synthesis is more pronounced in primary than metastatic colon cancer cells.
- 1 February 2016
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 100 (1) , 82-86
Targeting the expression of glutathione- and sulfate-dependent detoxification enzymes in HepG2 cells by oxygen in minimal and amino acid enriched medium
- 1 February 2016
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 100 (1) , 82-86
Targeting the expression of glutathione- and sulfate-dependent detoxification enzymes in HepG2 cells by oxygen in minimal and amino acid enriched medium
- 27 November 2015
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 14 (10) , 1328-1333
GSTP1 Polymorphisms and their Association with Glutathione Transferase and Peroxidase Activities in Patients with Motor Neuron Disease
Glutathione S-transferase pi (GSTP1) is a crucial enzyme in detoxification of electrophilic compounds and organic peroxides. Together with Se-dependent glutathione peroxidase (Se-GSHPx) it protects cells against oxidative stress which may be a primary factor implicated in motor neuron disease (MND) pathogenesis. We investigated GSTP1 polymorphisms and their relationship with GST and Se-GSTPx activities in a cohort of Polish patients with MND. Results were correlated with clinical phenotypes. The frequency of genetic variants for GSTP1 exon 5 (I105V) and exon 6 (A114V) was studied in 104 patients and 100 healthy controls using real-time polymerase chain reaction. GST transferase activity was determined in serum with 1-chloro-2,4-dinitrobenzene, its peroxidase activity with cumene hydroperoxide, and Se-GSHPx activity with hydrogen peroxide. There were no differences in the prevalence of GSTP1 polymorphism I105V and A114V between MND and controls, however the occurrence of CT variant in codon 114 was associated with a higher risk for MND. GSTP1 polymorphisms were less frequent in classic ALS than in progressive bulbar palsy. In classic ALS C* (heterozygous I /V and A /V) all studied activities were significantly lower than in classic ALS A* (homozygous I /I and A/A). GST peroxidase activity and Se-GSHPx activity were lower in classic ALS C* than in control C*, but in classic ALS A* Se-GSHPx activity was significantly higher than in control A*. It can be concluded that the presence of GSTP1 A114V but not I105V variant increases the risk of MND, and combined GSTP1 polymorphisms in codon 105 and 114 may result in lower protection of MND patients against the toxicity of electrophilic compounds, organic and inorganic hydroperoxides.
- 27 November 2015
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 14 (10) , 1328-1333
GSTP1 Polymorphisms and their Association with Glutathione Transferase and Peroxidase Activities in Patients with Motor Neuron Disease
Glutathione S-transferase pi (GSTP1) is a crucial enzyme in detoxification of electrophilic compounds and organic peroxides. Together with Se-dependent glutathione peroxidase (Se-GSHPx) it protects cells against oxidative stress which may be a primary factor implicated in motor neuron disease (MND) pathogenesis. We investigated GSTP1 polymorphisms and their relationship with GST and Se-GSTPx activities in a cohort of Polish patients with MND. Results were correlated with clinical phenotypes. The frequency of genetic variants for GSTP1 exon 5 (I105V) and exon 6 (A114V) was studied in 104 patients and 100 healthy controls using real-time polymerase chain reaction. GST transferase activity was determined in serum with 1-chloro-2,4-dinitrobenzene, its peroxidase activity with cumene hydroperoxide, and Se-GSHPx activity with hydrogen peroxide. There were no differences in the prevalence of GSTP1 polymorphism I105V and A114V between MND and controls, however the occurrence of CT variant in codon 114 was associated with a higher risk for MND. GSTP1 polymorphisms were less frequent in classic ALS than in progressive bulbar palsy. In classic ALS C* (heterozygous I /V and A /V) all studied activities were significantly lower than in classic ALS A* (homozygous I /I and A/A). GST peroxidase activity and Se-GSHPx activity were lower in classic ALS C* than in control C*, but in classic ALS A* Se-GSHPx activity was significantly higher than in control A*. It can be concluded that the presence of GSTP1 A114V but not I105V variant increases the risk of MND, and combined GSTP1 polymorphisms in codon 105 and 114 may result in lower protection of MND patients against the toxicity of electrophilic compounds, organic and inorganic hydroperoxides.
- 1 August 2014
- Published by Elsevier in Clinical Biochemistry
- Vol. 47 (12) , 1056-1059
Significance of arginase determination in body fluids of patients with hepatocellular carcinoma and liver cirrhosis before and after surgical treatment
- 1 August 2014
- Published by Elsevier in Clinical Biochemistry
- Vol. 47 (12) , 1056-1059
Significance of arginase determination in body fluids of patients with hepatocellular carcinoma and liver cirrhosis before and after surgical treatment
- Open Access
- 28 September 2013
- Published by Springer Nature in Neurochemical Research
- Vol. 38 (12) , 2463-2473
Dynactin Deficiency in the CNS of Humans with Sporadic ALS and Mice with Genetically Determined Motor Neuron Degeneration
Dynactin is a complex motor protein involved in the retrograde axonal transport disturbances of which may lead to amyotrophic lateral sclerosis (ALS). Mice with hSOD1G93A mutation develop ALS-like symptoms and are used as a model for the disease studies. Similar symptoms demonstrate Cra1 mice, with Dync1h1 mutation. Dynactin heavy (DCTN1) and light (DCTN3) subunits were studied in the CNS of humans with sporadic ALS (SALS), mice with hSOD1G93A (SOD1/+), Dync1h1 (Cra1/+), and double (Cra1/SOD1) mutation at presymptomatic and symptomatic stages. In SALS subjects, in contrast to control cases, expression of DCTN1-mRNA but not DCTN3-mRNA in the motor cortex was higher than in the sensory cortex. However, the mean levels of DCTN1-mRNA and protein were lower in both SALS cortexes and in the spinal cord than in control structures. DCTN3 was unchanged in brain cortexes but decreased in the spinal cord on both mRNA and protein levels. In all SALS tissues immunohistochemical analyses revealed degeneration and loss of neuronal cells, and poor expression of dynactin subunits. In SOD1/+ mice both subunits expression was significantly lower in the frontal cortex, spinal cord and hippocampus than in wild-type controls, especially at presymptomatic stage. Fewer changes occurred in Cra1/SOD1 and Cra1/+ mice.It can be concluded that in sporadic and SOD1-related ALS the impairment of axonal retrograde transport may be due to dynactin subunits deficiency and subsequent disturbances of the whole dynein/dynactin complex structure and function. The Dync1h1 mutation itself has slight negative effect on dynactin expression and it alleviates the changes caused by SOD1G93A mutation.
- 28 September 2013
- Published by Springer Nature in Neurochemical Research
- Vol. 38 (12) , 2463-2473
Open AccessDynactin Deficiency in the CNS of Humans with Sporadic ALS and Mice with Genetically Determined Motor Neuron Degeneration
Dynactin is a complex motor protein involved in the retrograde axonal transport disturbances of which may lead to amyotrophic lateral sclerosis (ALS). Mice with hSOD1G93A mutation develop ALS-like symptoms and are used as a model for the disease studies. Similar symptoms demonstrate Cra1 mice, with Dync1h1 mutation. Dynactin heavy (DCTN1) and light (DCTN3) subunits were studied in the CNS of humans with sporadic ALS (SALS), mice with hSOD1G93A (SOD1/+), Dync1h1 (Cra1/+), and double (Cra1/SOD1) mutation at presymptomatic and symptomatic stages. In SALS subjects, in contrast to control cases, expression of DCTN1-mRNA but not DCTN3-mRNA in the motor cortex was higher than in the sensory cortex. However, the mean levels of DCTN1-mRNA and protein were lower in both SALS cortexes and in the spinal cord than in control structures. DCTN3 was unchanged in brain cortexes but decreased in the spinal cord on both mRNA and protein levels. In all SALS tissues immunohistochemical analyses revealed degeneration and loss of neuronal cells, and poor expression of dynactin subunits. In SOD1/+ mice both subunits expression was significantly lower in the frontal cortex, spinal cord and hippocampus than in wild-type controls, especially at presymptomatic stage. Fewer changes occurred in Cra1/SOD1 and Cra1/+ mice.It can be concluded that in sporadic and SOD1-related ALS the impairment of axonal retrograde transport may be due to dynactin subunits deficiency and subsequent disturbances of the whole dynein/dynactin complex structure and function. The Dync1h1 mutation itself has slight negative effect on dynactin expression and it alleviates the changes caused by SOD1G93A mutation.
- 15 May 2008
- Vol. 62, 206-13
[New insights into arginase. Part I. Structure and characteristics].
Arginase (amidinohydrolase, EC 3.5.3.1) is present in all living organisms, i.e. bacteria, yeasts, plants, invertebrates, and vertebrates. In ureolitic organisms, arginase expresses the highest activity in the liver, where it takes part in ammonia detoxifi cation. Arginase activity is much lower in extrahepatic tissues and its physiological function is still poorly understood; however, it seems to be involved in L-arginine metabolism. Arginase is a homotrimer consisting of 20- to 40-kDa subunits acting at a pH of 10 and in the presence of manganese ions. Proline, ornithine, and NG-hydroxy-L-arginine, an intermediate in the biosynthesis of NO, are known as competitive arginase inhibitors. Two arginase isoenzymes, AI (the so-called "hepatic arginase") and AII ("extrahepatic arginase") are present in mammalian tissues. There are signifi cant differences between the isoenzymes regarding their subcellular localization, isoelectric point, substrate affinity, and immunological cross-reactivity. Arginase isoenzymes AI and AII have high substrate specifi city, but the affi nity to L-arginine is higher for isoenzyme AI than AII. Both isoenzymes exist in most tissues and their expressions change depending on the functional state and metabosynlic requirements. Besides differences in the amino-acid content of the arginase isoforms within one or different species, they have highly conserved regions responsible for the structure and catalytic properties of arginase.
- 15 May 2008
- Vol. 62, 206-13
[New insights into arginase. Part I. Structure and characteristics].
Arginase (amidinohydrolase, EC 3.5.3.1) is present in all living organisms, i.e. bacteria, yeasts, plants, invertebrates, and vertebrates. In ureolitic organisms, arginase expresses the highest activity in the liver, where it takes part in ammonia detoxifi cation. Arginase activity is much lower in extrahepatic tissues and its physiological function is still poorly understood; however, it seems to be involved in L-arginine metabolism. Arginase is a homotrimer consisting of 20- to 40-kDa subunits acting at a pH of 10 and in the presence of manganese ions. Proline, ornithine, and NG-hydroxy-L-arginine, an intermediate in the biosynthesis of NO, are known as competitive arginase inhibitors. Two arginase isoenzymes, AI (the so-called "hepatic arginase") and AII ("extrahepatic arginase") are present in mammalian tissues. There are signifi cant differences between the isoenzymes regarding their subcellular localization, isoelectric point, substrate affinity, and immunological cross-reactivity. Arginase isoenzymes AI and AII have high substrate specifi city, but the affi nity to L-arginine is higher for isoenzyme AI than AII. Both isoenzymes exist in most tissues and their expressions change depending on the functional state and metabosynlic requirements. Besides differences in the amino-acid content of the arginase isoforms within one or different species, they have highly conserved regions responsible for the structure and catalytic properties of arginase.
- 14 May 2008
- Vol. 62, 214-21
[New insights into arginase. Part II. Role in physiology and pathology].
Arginase (amidinohydrolase, EC 3.5.3.1) is known as the last enzyme in the urea cycle in the liver, but it is also present in extrahepatic tissues. Arginase hydrolyzes L-arginine to L-ornithine and urea and its biochemical and physiological role varies depending on the organism and tissue. Besides its participation in ammonia detoxification, arginase is involved in the synthesis of polyamines, crucial for the proper course of many metabolic processes, proline, the main connective tissues protein, and glutamates, amino acids which take part in nitric metabolism, important in the nervous system and also a substrate for protein synthesis. The competition of arginase with nitric oxide synthase (NOS) for the common substrate L-arginine indicates its participation in the regulation of nitric oxide (NO) synthesis. The physiological role of arginase and its common occurrence indicate its engagement in many pathologies. Due to its competition with NOS for arginine and its participation in proline synthesis, arginase plays an important role in such diseases as cerebral stroke, trauma, inflammation, and depression, whereas its participation in polyamine synthesis indicates arginase's engagement in the development of neoplastic diseases in the human organism.
- 14 May 2008
- Vol. 62, 214-21
[New insights into arginase. Part II. Role in physiology and pathology].
Arginase (amidinohydrolase, EC 3.5.3.1) is known as the last enzyme in the urea cycle in the liver, but it is also present in extrahepatic tissues. Arginase hydrolyzes L-arginine to L-ornithine and urea and its biochemical and physiological role varies depending on the organism and tissue. Besides its participation in ammonia detoxification, arginase is involved in the synthesis of polyamines, crucial for the proper course of many metabolic processes, proline, the main connective tissues protein, and glutamates, amino acids which take part in nitric metabolism, important in the nervous system and also a substrate for protein synthesis. The competition of arginase with nitric oxide synthase (NOS) for the common substrate L-arginine indicates its participation in the regulation of nitric oxide (NO) synthesis. The physiological role of arginase and its common occurrence indicate its engagement in many pathologies. Due to its competition with NOS for arginine and its participation in proline synthesis, arginase plays an important role in such diseases as cerebral stroke, trauma, inflammation, and depression, whereas its participation in polyamine synthesis indicates arginase's engagement in the development of neoplastic diseases in the human organism.
- 1 January 2007
- Vol. 60, 215-8
[Serum arginase activity in patients with liver cirrhosis and hepatocellular carcinoma].
Preoperative and postoperative arginase activity was determined in blood serum of 25 patients with liver cirrhosis and 25 patients with hepatocellular carcinoma. The rise of serum arginase activity was observed in the majority of patients before the surgery and the decrease after tumor resection or liver transplantation. The preoperative values of serum arginase activity were similar in both groups of patients. A presence of additional, anionic arginase isoform (All) was demonstrated in serum of studied patients, which was absent in healthy subjects. Thus, our results indicate that the arginase activity cannot differentiate liver cirrhosis and hepatocellular carcinoma. However, arginase isoform All seems to be specific for studied liver diseases.
- 1 January 2007
- Vol. 60, 215-8
[Serum arginase activity in patients with liver cirrhosis and hepatocellular carcinoma].
Preoperative and postoperative arginase activity was determined in blood serum of 25 patients with liver cirrhosis and 25 patients with hepatocellular carcinoma. The rise of serum arginase activity was observed in the majority of patients before the surgery and the decrease after tumor resection or liver transplantation. The preoperative values of serum arginase activity were similar in both groups of patients. A presence of additional, anionic arginase isoform (All) was demonstrated in serum of studied patients, which was absent in healthy subjects. Thus, our results indicate that the arginase activity cannot differentiate liver cirrhosis and hepatocellular carcinoma. However, arginase isoform All seems to be specific for studied liver diseases.
- 1 January 2004
- Vol. 16 (91) , 31-3
[Arginase as a marker of cancerogenesis. III. Comparison of arginase activity with CEA and Ca 19-9 in liver metastases of colorectal cancer].
Preoperative activity of arginase was determined in blood serum of 86 patients with colorectal liver metastases and compared with the level of CEA and Ca 19-9. Arginase activity was elevated in 94% patients, whereas the levels of CEA and CA 19-9 were higher in 63% and 45% patients, respectively. The number of not detected by each marker cases (false negative) was much lower in arginase determination (only 6%) than in CEA (37s%), and Ca 19-9 (55%). Sensitivity and specificity of arginase test was much higher than these of CEA and Ca 19-9. The combination of CEA or Ca 19-9 with arginase determination improved the sensitivity of either test, but the combined parameters were still lower than these for arginase itself. Obtained results indicate that arginase test demonstrate higher clinical value in the early diagnosis of colorectal liver metastases than CEA and Ca 19-9.
- 1 January 2004
- Vol. 16 (91) , 31-3
[Arginase as a marker of cancerogenesis. III. Comparison of arginase activity with CEA and Ca 19-9 in liver metastases of colorectal cancer].
Preoperative activity of arginase was determined in blood serum of 86 patients with colorectal liver metastases and compared with the level of CEA and Ca 19-9. Arginase activity was elevated in 94% patients, whereas the levels of CEA and CA 19-9 were higher in 63% and 45% patients, respectively. The number of not detected by each marker cases (false negative) was much lower in arginase determination (only 6%) than in CEA (37s%), and Ca 19-9 (55%). Sensitivity and specificity of arginase test was much higher than these of CEA and Ca 19-9. The combination of CEA or Ca 19-9 with arginase determination improved the sensitivity of either test, but the combined parameters were still lower than these for arginase itself. Obtained results indicate that arginase test demonstrate higher clinical value in the early diagnosis of colorectal liver metastases than CEA and Ca 19-9.